Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Nov 4, 2024, 4:00 PM
1.070
+0.040 (3.88%)
After-hours: Nov 4, 2024, 5:34 PM EST
Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences.
Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc.
Country | United States |
Founded | 2011 |
IPO Date | Jun 2, 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 30 |
CEO | George Lasezkay |
Contact Details
Address: 900 North Point Parkway, Suite 200 Alpharetta, Georgia 30005 United States | |
Phone | 678 270 3631 |
Website | clearsidebio.com |
Stock Details
Ticker Symbol | CLSD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001539029 |
CUSIP Number | 185063104 |
ISIN Number | US1850631045 |
Employer ID | 45-2437375 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, Chief Executive Officer and Director |
Charles A. Deignan | Chief Financial Officer |
Jenny R. Kobin | Head of Investor Relations |
Rick McElheny | Senior Vice President of Corporate Development and Alliance Management |
Rafael V. Andino | Senior Vice President of Engineering and Manufacturing |
Susan L. Coultas Ph.D. | Chief Clinical Officer |
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
Leslie B. Zacks | Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 9, 2024 | 8-K | Current Report |
Aug 12, 2024 | 10-Q | Quarterly Report |
Aug 12, 2024 | 8-K | Current Report |
Jul 24, 2024 | 8-K | Current Report |
Jun 20, 2024 | 8-K | Current Report |
May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 10, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | 8-K | Current Report |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |